Clinical Trial

A Study to Evaluate MWN109 Injection in Healthy Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2025 (before its estimated September 25, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-28.
Status change: Not Yet Recruiting → Recruiting 2025-04-11
Trial Details
NCT Number NCT06859853
Lead Sponsor Shanghai Minwei Biotechnology Co., Ltd
Conditions Overweight or Obese
Enrollment 72 participants
Start Date 2025-03-17
Primary Completion 2025-09-25 (estimated)
Study Completion 2025-11-25 (estimated)
Updated on ClinicalTrials.gov 2025-04-15